Antares Pharma (NASDAQ:ATRS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday.
A number of other brokerages have also issued reports on ATRS. ValuEngine raised Antares Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, July 5th. HC Wainwright set a $4.00 target price on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $4.00 target price on shares of Antares Pharma in a research report on Friday, August 17th.
Shares of Antares Pharma stock opened at $3.21 on Friday. The firm has a market cap of $516.39 million, a PE ratio of -29.18 and a beta of 0.34. The company has a current ratio of 2.33, a quick ratio of 1.89 and a debt-to-equity ratio of 1.01. Antares Pharma has a 12-month low of $1.58 and a 12-month high of $4.09.
In related news, CEO Robert F. Apple sold 43,000 shares of the company’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total transaction of $161,250.00. Following the transaction, the chief executive officer now directly owns 1,573,562 shares of the company’s stock, valued at $5,900,857.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jacques Gonella sold 49,507 shares of the company’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $3.09, for a total value of $152,976.63. Following the transaction, the director now directly owns 9,985,848 shares in the company, valued at $30,856,270.32. The disclosure for this sale can be found here. Insiders have sold 343,000 shares of company stock worth $1,088,250 over the last three months. 12.20% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Antares Pharma by 7.3% during the second quarter. BlackRock Inc. now owns 9,805,325 shares of the specialty pharmaceutical company’s stock valued at $25,298,000 after buying an additional 664,681 shares during the period. FMR LLC grew its stake in Antares Pharma by 38.8% in the second quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock valued at $9,393,000 after purchasing an additional 1,018,300 shares in the last quarter. Mycio Wealth Partners LLC purchased a new position in Antares Pharma in the second quarter valued at about $6,278,000. Wells Fargo & Company MN grew its stake in Antares Pharma by 21.5% in the first quarter. Wells Fargo & Company MN now owns 1,933,469 shares of the specialty pharmaceutical company’s stock valued at $4,253,000 after purchasing an additional 342,062 shares in the last quarter. Finally, JW Asset Management LLC grew its stake in Antares Pharma by 2.8% in the second quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock valued at $4,697,000 after purchasing an additional 50,000 shares in the last quarter. 38.93% of the stock is currently owned by hedge funds and other institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.